Rhea Clopidogrel Bisulfate Dosage/Direction for Use

General: Recent MI, Recent Stroke, or Established Peripheral Arterial Disease: Clopidogrel should be given as a single dose of 75 mg.
Acute Coronary Syndrome: For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI), clopidogrel should be initiated with a single 300-mg loading dose and then continued at 75 mg once daily. Acetylsalicylic acid (ASA) (75 mg up to 325 mg once daily) should be initiated and continued in combination with clopidogrel. In CURE, most patients with Acute Coronary Syndrome also received heparin.
For patients with ST-segment elevation acute myocardial infarction, the recommended dose of clopidogrel is 75 mg once daily, administered in combination with ASA, with or without thrombolytics. Clopidogrel may be initiated with or without a loading dose (300 mg was used in CLARITY).
Atrial Fibrillation: Clopidogrel should be given as a single dose of 75 mg. ASA (75-100 mg daily should be initiated and continued in combination with clopidogrel.
Pharmacogenetics: CYP2C19 poor metaboliser status is associated with diminished antiplatelet response to clopidogrel. A higher dose regimen (600-mg loading dose followed by 150 mg once daily) in poor metabolisers increases antiplatelet response. Consider the use of higher clopidogrel doses in patients who are poor CYP2C19 metabolisers. An appropriate dose regimen for this patient population has not been established in clinical outcome trials.
Special Populations: Children: Safety and effectiveness in pediatric populations have not been established.
Elderly: No dosage adjustment is necessary in elderly patients.
Hepatic impairment: No dosage adjustment is necessary. See Precautions.
Renal impairment: No dosage adjustment is necessary. See Precautions.
Administration: Clopidogrel can be administered with or without food.